New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: The example of Kenya

Bulletin of the World Health Organization

Volumn 87, Issue 3, 2009, Pages 186-192

  Mansoer, John ^a   Scheele, Suzanne ^b   Floyd, Katherine ^b   Dye, Christopher ^b   Sitienei, Joseph ^c   Williams, Brian ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Natl Leprosy/TB Contr Prog Kenya   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

DETECTION METHOD; DISEASE CONTROL; DISEASE PREVALENCE; HUMAN IMMUNODEFICIENCY VIRUS; TUBERCULOSIS;

ADULT; ARTICLE; CASE DETECTION RATE; DIAGNOSTIC ACCURACY; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MEDICAL STAFF; METHODOLOGY; PREVALENCE; SPUTUM SMEAR; TUBERCULOSIS;

ADOLESCENT; ADULT; ALGORITHMS; COMORBIDITY; FORECASTING; HIV INFECTIONS; HUMANS; KENYA; MIDDLE AGED; TUBERCULOSIS; YOUNG ADULT;

AFRICA; EAST AFRICA; KENYA; SUB-SAHARAN AFRICA;

EID: 61449135959     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.08.051474     Document Type: Article

References (32)

1. Stop TB Partnership. The global plan to stop TB, 2006-2015. Geneva: World Health Organization; 2006.
2. Global tuberculosis control: surveillance, planning, financing. Geneva: World Health Organization; 2007.
3. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC, Global burden of tuberculosis, Estimated incidence, prevalence, and mortality by country, JAMA 1999;282:677-86, PMID:10517722 doi:10.1001/jama.282.7.677
4. Dye C, Bassili A, Bierrenbach AL, Broekmans JF, Chadha VK, Glaziou P, et al, Measuring tuberculosis burden, trends, and the impact of control programmes, Lancet Infect Dis 2008;8:233-43. PMID:18201929 doi: 10.1016/S1473- 3099(07)70291-8
5. National Aids Control Council. Country Report - Kenya. UNGASS 2006: United Nations General Assembly Special Session on HIV/AIDS. Nairobi: NACC; 2006,
6. Kenya, Ministry of Health. AIDS in Kenya: trends, interventions and impact. 7th edn. Nairobi: National AIDS and STI Control Programme; 2005, Available from: http://www.policyproject.com/pubs/countryreports/KEN-AIDS-7thEd. pdf [accessed on 6 January 2009].
7. van Gorkom J, Kibuga D, Abdallah S, Adungosi J, Aluvaala B, Kanganai J, et al. HIV-seroprevalence among tuberculosis patients in Kenya. East Afr Med J 1999;76:452-6. PMID:10520351
8. Corbett EL, Charalambous S, Moloi VM, Fielding K, Grant AD, Dye C, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 2004;170:673-9. PMID:15191919 doi:10.1164/rccm.200405-5900C
9. Corbett EL, Charalambous S, Fielding K, Clayton T, Hayes RJ, De Cock KM, et al, Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis 2003; 188:1156-63. PMID:14551886 doi:10.1086/378519
10. Williams B, Maher D. Tuberculosis fuelled by HIV: putting out the flames. Am J Respir Crit Care Med 2007; 175:6-8. PMID:17179495 doi:10.1164/ rccm. 200609-1376ED
11. Espinal MA, Peréz EN, Baéz J, Henriquez L, Fernandez K, Lopez M, et al. Infectiousness of Mycobacterium tuberculosis in HIV-1 - infected patients with tuberculosis: a prospective study. Lancet 2000;355:275-80. PMID:10675075 doi: 10.1016/S0140-6736(99)04402-5
12. Williams BG, Dye C, Antiretroviral drugs for tuberculosis control in the era Of HIV/AIDS. Science 2003;301:1535-7.PMID:12920302 doi:10.1126/science. 1086845
13. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S, Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43:42-6. PMID:16885778 doi:10.1097/01. qai.0000230521.86964.86
14. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al, Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-95. PMID:15060436 doi: 10.1097/00002030-200404090-00006
15. Lee MP, Chan JW, Ng KK, Li PC, Clinical manifestations of tuberculosis in HIV-infected patients. Respirology 2000;5:423-6. PMID:11192558 doi:10.1046/j.1440-1843.2000.00287.X
16. von Reyn CF. The significance of bacteremic tuberculosis among persons with HIV infection in developing countries. AIDS 1999;13:2193-5. PMID: 10563704 doi:10.1097/00002030-199911120-00001
17. Lawn SD, Wood R. Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries. Clin Infect Dis 2005; 41:1783-6. PMID:16288404 doi:10.1086/498308
18. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al, CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: Implications for prophylaxis and treatment, J Acquir Immune Defic Syndr 2006; 42:464-9. PMID:16810113 doi:10.1097/01.qai.0000225729.79610.b7
19. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S, How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191:150-8. PMID: 15609223 doi:10.1086/426827
20. Moreno S, Baraia-Etxaburu J, Bouza E, Parras F, Pérez- Tascón M, Miralles P, et al. Risk for developing tuberculosis among anergic patients infected with HIV Ann Intern Med 1993;119:194-8. PMID:8100693
21. Girardi E, Antonucci G, Vanacore P, Libanore M, Errante I, Matteelli A, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection, AIDS 2000; 14:1985-91, PMID: 10997404 doi:10.1097/00002030-200009080-00015
22. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al, A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection, N Engl J Med 1989; 320:545-50, PMID:2915665
23. Dupon M, Texier-Maugein J, Leroy V, Sentilhes A, Pellegrin JL, Morlat P, et al, Tuberculosis and HIV infection: a cohort study of incidence and susceptibility to antituberculous drugs, Bordeaux, 1985-1993, AIDS 1995;9:577-83. PMID7662196 doi:10.1097/00002030-199506000-00008
24. Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993;7:1345-9. PMID:8267907 doi:10.1097/00002030-199310000-00007
25. The Antiretroviral Therapy Cohort Collaboration. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005;41:1772-82. PMID:16288403 doi:10.1086/498315
26. Badri M, Wilson D, Wood R, Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359:2059-6. PMID:12086758 doi:10.1016/S0140-6736(02)08904-3
27. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687-93. PMID: 11728545 doi:10.1016/S01406736(01)06712-5
28. Williams B, Gouws E, Wilkinson D, Abdool Karim S, Estimating HIV incidence rates from age prevalence data in epidemic situations. Stat Med 2001;20:2003-16. PMID: 11427956 doi:10.1002/sim.840
29. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV Nat Rev Immunol 2005;5:819-26. PMID:16200083 doi:10.1038/nri1704
30. Joint United Nations Programme on HIV/AIDS. 2008 report on the global AIDS epidemic. Geneva: UNAIDS; 2008.
31. Global tuberculosis control: surveillance, planning, financing. Geneva: World Health Organization; 2008. Available from: http://www.unaids.org/ en/[accessed on 6 January 2009].
32. Resolution A/55/2. United Nations Millennium Declaration. Fifty-fifth United Nations General Assembly, New York, 18 September 2000 (Document A/ RES/53/202).